tiprankstipranks
Verve Therapeutics sees cash runway into mid-2027
The Fly

Verve Therapeutics sees cash runway into mid-2027

With Verve’s existing cash, cash equivalents and marketable securities, including the milestone payment to be received from Lilly under the Lp(a) program, Verve expects its capital position to be sufficient to fund its operations into mid-2027.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles